nodes	percent_of_prediction	percent_of_DWPC	metapath
Argatroban—CYP3A4—Thiotepa—urinary bladder cancer	0.0959	0.465	CbGbCtD
Argatroban—CYP3A5—Etoposide—urinary bladder cancer	0.0667	0.323	CbGbCtD
Argatroban—F2—urine—urinary bladder cancer	0.0394	0.355	CbGeAlD
Argatroban—CYP3A4—Etoposide—urinary bladder cancer	0.026	0.126	CbGbCtD
Argatroban—F2—IL1 and megakaryotyces in obesity—S100A9—urinary bladder cancer	0.0254	0.14	CbGpPWpGaD
Argatroban—CYP3A4—Doxorubicin—urinary bladder cancer	0.0177	0.086	CbGbCtD
Argatroban—F2—prostate gland—urinary bladder cancer	0.0142	0.127	CbGeAlD
Argatroban—CYP3A4—urine—urinary bladder cancer	0.012	0.108	CbGeAlD
Argatroban—F2—epithelium—urinary bladder cancer	0.0104	0.0936	CbGeAlD
Argatroban—F2—renal system—urinary bladder cancer	0.00965	0.0868	CbGeAlD
Argatroban—F2—female reproductive system—urinary bladder cancer	0.00773	0.0696	CbGeAlD
Argatroban—F2—Regulation of IGF Activity by IGFBP—IGFBP3—urinary bladder cancer	0.00706	0.0389	CbGpPWpGaD
Argatroban—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00687	0.0378	CbGpPWpGaD
Argatroban—CYP3A5—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00683	0.0376	CbGpPWpGaD
Argatroban—CYP3A5—prostate gland—urinary bladder cancer	0.00573	0.0516	CbGeAlD
Argatroban—CYP3A5—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00554	0.0305	CbGpPWpGaD
Argatroban—F2—Folate Metabolism—SLC19A1—urinary bladder cancer	0.00504	0.0278	CbGpPWpGaD
Argatroban—CYP3A5—renal system—urinary bladder cancer	0.00391	0.0352	CbGeAlD
Argatroban—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00359	0.0198	CbGpPWpGaD
Argatroban—F2—PAR4-mediated thrombin signaling events—RHOA—urinary bladder cancer	0.00358	0.0197	CbGpPWpGaD
Argatroban—F2—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.00357	0.0197	CbGpPWpGaD
Argatroban—F2—Blood Clotting Cascade—PLAU—urinary bladder cancer	0.00353	0.0194	CbGpPWpGaD
Argatroban—F2—Vitamin B12 Metabolism—MPO—urinary bladder cancer	0.00345	0.019	CbGpPWpGaD
Argatroban—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00318	0.0175	CbGpPWpGaD
Argatroban—F2—Regulation of IGF Activity by IGFBP—IGF1—urinary bladder cancer	0.00298	0.0164	CbGpPWpGaD
Argatroban—CYP3A4—renal system—urinary bladder cancer	0.00293	0.0264	CbGeAlD
Argatroban—CYP3A5—vagina—urinary bladder cancer	0.00283	0.0255	CbGeAlD
Argatroban—F2—Folate Metabolism—MPO—urinary bladder cancer	0.00281	0.0154	CbGpPWpGaD
Argatroban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00266	0.0146	CbGpPWpGaD
Argatroban—CYP3A5—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00262	0.0144	CbGpPWpGaD
Argatroban—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00258	0.0142	CbGpPWpGaD
Argatroban—CYP3A4—female reproductive system—urinary bladder cancer	0.00235	0.0211	CbGeAlD
Argatroban—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00226	0.0125	CbGpPWpGaD
Argatroban—F2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.00223	0.0123	CbGpPWpGaD
Argatroban—F2—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.00217	0.0119	CbGpPWpGaD
Argatroban—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00215	0.0119	CbGpPWpGaD
Argatroban—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00214	0.0118	CbGpPWpGaD
Argatroban—F2—Syndecan-4-mediated signaling events—RHOA—urinary bladder cancer	0.00195	0.0107	CbGpPWpGaD
Argatroban—F2—IL1 and megakaryotyces in obesity—MMP9—urinary bladder cancer	0.00195	0.0107	CbGpPWpGaD
Argatroban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00194	0.0107	CbGpPWpGaD
Argatroban—F2—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	0.00191	0.0105	CbGpPWpGaD
Argatroban—Cardiac arrest—Etoposide—urinary bladder cancer	0.00187	0.00372	CcSEcCtD
Argatroban—Pleural effusion—Doxorubicin—urinary bladder cancer	0.00183	0.00365	CcSEcCtD
Argatroban—Diarrhoea—Mitomycin—urinary bladder cancer	0.00183	0.00365	CcSEcCtD
Argatroban—Pneumonia—Gemcitabine—urinary bladder cancer	0.00178	0.00356	CcSEcCtD
Argatroban—Dizziness—Mitomycin—urinary bladder cancer	0.00177	0.00352	CcSEcCtD
Argatroban—F2—Folate Metabolism—SOD2—urinary bladder cancer	0.00176	0.0097	CbGpPWpGaD
Argatroban—Pneumonia—Fluorouracil—urinary bladder cancer	0.00175	0.0035	CcSEcCtD
Argatroban—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.00175	0.00348	CcSEcCtD
Argatroban—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.00174	0.00347	CcSEcCtD
Argatroban—Vasodilation—Epirubicin—urinary bladder cancer	0.00172	0.00344	CcSEcCtD
Argatroban—Vasodilation procedure—Epirubicin—urinary bladder cancer	0.00172	0.00344	CcSEcCtD
Argatroban—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.00172	0.00343	CcSEcCtD
Argatroban—Angiopathy—Thiotepa—urinary bladder cancer	0.00171	0.00342	CcSEcCtD
Argatroban—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.00171	0.00341	CcSEcCtD
Argatroban—Vomiting—Mitomycin—urinary bladder cancer	0.0017	0.00339	CcSEcCtD
Argatroban—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00169	0.00338	CcSEcCtD
Argatroban—Haematuria—Gemcitabine—urinary bladder cancer	0.00169	0.00337	CcSEcCtD
Argatroban—Rash—Mitomycin—urinary bladder cancer	0.00168	0.00336	CcSEcCtD
Argatroban—Dermatitis—Mitomycin—urinary bladder cancer	0.00168	0.00336	CcSEcCtD
Argatroban—F2—Folate Metabolism—GPX1—urinary bladder cancer	0.00168	0.00925	CbGpPWpGaD
Argatroban—Headache—Mitomycin—urinary bladder cancer	0.00167	0.00334	CcSEcCtD
Argatroban—Respiratory failure—Methotrexate—urinary bladder cancer	0.00165	0.00329	CcSEcCtD
Argatroban—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.00163	0.00325	CcSEcCtD
Argatroban—Pulmonary embolism—Methotrexate—urinary bladder cancer	0.00162	0.00323	CcSEcCtD
Argatroban—Myocardial infarction—Cisplatin—urinary bladder cancer	0.00162	0.00323	CcSEcCtD
Argatroban—F2—Complement and Coagulation Cascades—PLAU—urinary bladder cancer	0.0016	0.00882	CbGpPWpGaD
Argatroban—Haemoglobin—Gemcitabine—urinary bladder cancer	0.0016	0.00319	CcSEcCtD
Argatroban—Vasodilation procedure—Doxorubicin—urinary bladder cancer	0.0016	0.00319	CcSEcCtD
Argatroban—Vasodilation—Doxorubicin—urinary bladder cancer	0.0016	0.00319	CcSEcCtD
Argatroban—Back pain—Thiotepa—urinary bladder cancer	0.00159	0.00318	CcSEcCtD
Argatroban—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00159	0.00317	CcSEcCtD
Argatroban—Nausea—Mitomycin—urinary bladder cancer	0.00159	0.00317	CcSEcCtD
Argatroban—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00157	0.00314	CcSEcCtD
Argatroban—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00156	0.00312	CcSEcCtD
Argatroban—F2—Folate Metabolism—MTHFR—urinary bladder cancer	0.00155	0.00854	CbGpPWpGaD
Argatroban—F2—Syndecan-4-mediated signaling events—MMP9—urinary bladder cancer	0.00155	0.00853	CbGpPWpGaD
Argatroban—F2—PAR1-mediated thrombin signaling events—RHOA—urinary bladder cancer	0.00154	0.00848	CbGpPWpGaD
Argatroban—Pneumonia—Etoposide—urinary bladder cancer	0.00152	0.00304	CcSEcCtD
Argatroban—Pulmonary embolism—Epirubicin—urinary bladder cancer	0.00152	0.00303	CcSEcCtD
Argatroban—Ventricular tachycardia—Epirubicin—urinary bladder cancer	0.00152	0.00303	CcSEcCtD
Argatroban—Bradycardia—Cisplatin—urinary bladder cancer	0.00151	0.00301	CcSEcCtD
Argatroban—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.00149	0.00298	CcSEcCtD
Argatroban—Myocardial infarction—Etoposide—urinary bladder cancer	0.00148	0.00296	CcSEcCtD
Argatroban—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.00146	0.00807	CbGpPWpGaD
Argatroban—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00144	0.00795	CbGpPWpGaD
Argatroban—Angiopathy—Gemcitabine—urinary bladder cancer	0.00144	0.00288	CcSEcCtD
Argatroban—Pulmonary oedema—Methotrexate—urinary bladder cancer	0.00144	0.00288	CcSEcCtD
Argatroban—Cough—Thiotepa—urinary bladder cancer	0.00144	0.00287	CcSEcCtD
Argatroban—F2—Thrombin signalling through proteinase activated receptors (PARs)—SRC—urinary bladder cancer	0.00143	0.00786	CbGpPWpGaD
Argatroban—Sepsis—Methotrexate—urinary bladder cancer	0.0014	0.00281	CcSEcCtD
Argatroban—Pulmonary embolism—Doxorubicin—urinary bladder cancer	0.0014	0.0028	CcSEcCtD
Argatroban—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.0014	0.0028	CcSEcCtD
Argatroban—F2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.0014	0.00771	CbGpPWpGaD
Argatroban—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.00139	0.00765	CbGpPWpGaD
Argatroban—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.00139	0.00765	CbGpPWpGaD
Argatroban—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00139	0.00764	CbGpPWpGaD
Argatroban—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00137	0.00754	CbGpPWpGaD
Argatroban—Thrombophlebitis—Methotrexate—urinary bladder cancer	0.00136	0.00271	CcSEcCtD
Argatroban—Confusional state—Thiotepa—urinary bladder cancer	0.00135	0.0027	CcSEcCtD
Argatroban—Pulmonary oedema—Epirubicin—urinary bladder cancer	0.00135	0.00269	CcSEcCtD
Argatroban—Back pain—Gemcitabine—urinary bladder cancer	0.00134	0.00267	CcSEcCtD
Argatroban—F2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.00134	0.00735	CbGpPWpGaD
Argatroban—Infection—Thiotepa—urinary bladder cancer	0.00133	0.00266	CcSEcCtD
Argatroban—Sepsis—Epirubicin—urinary bladder cancer	0.00131	0.00263	CcSEcCtD
Argatroban—Tachycardia—Thiotepa—urinary bladder cancer	0.00131	0.00262	CcSEcCtD
Argatroban—Renal failure acute—Methotrexate—urinary bladder cancer	0.00127	0.00254	CcSEcCtD
Argatroban—F2—Platelet Aggregation (Plug Formation)—SRC—urinary bladder cancer	0.00127	0.007	CbGpPWpGaD
Argatroban—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.00127	0.00254	CcSEcCtD
Argatroban—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.00127	0.00699	CbGpPWpGaD
Argatroban—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00125	0.0069	CbGpPWpGaD
Argatroban—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.00125	0.00249	CcSEcCtD
Argatroban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00123	0.0068	CbGpPWpGaD
Argatroban—F2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.00123	0.00678	CbGpPWpGaD
Argatroban—Angiopathy—Etoposide—urinary bladder cancer	0.00123	0.00246	CcSEcCtD
Argatroban—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00122	0.00671	CbGpPWpGaD
Argatroban—Sepsis—Doxorubicin—urinary bladder cancer	0.00122	0.00243	CcSEcCtD
Argatroban—Cough—Gemcitabine—urinary bladder cancer	0.00121	0.00241	CcSEcCtD
Argatroban—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.0012	0.00239	CcSEcCtD
Argatroban—Renal failure acute—Epirubicin—urinary bladder cancer	0.00119	0.00238	CcSEcCtD
Argatroban—Dyspepsia—Thiotepa—urinary bladder cancer	0.00118	0.00236	CcSEcCtD
Argatroban—Chest pain—Gemcitabine—urinary bladder cancer	0.00118	0.00235	CcSEcCtD
Argatroban—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.00118	0.00235	CcSEcCtD
Argatroban—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00116	0.00231	CcSEcCtD
Argatroban—Chest pain—Fluorouracil—urinary bladder cancer	0.00116	0.00231	CcSEcCtD
Argatroban—Renal impairment—Epirubicin—urinary bladder cancer	0.00116	0.00231	CcSEcCtD
Argatroban—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.00115	0.0023	CcSEcCtD
Argatroban—Pain—Thiotepa—urinary bladder cancer	0.00115	0.00229	CcSEcCtD
Argatroban—Constipation—Thiotepa—urinary bladder cancer	0.00115	0.00229	CcSEcCtD
Argatroban—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.00114	0.0063	CbGpPWpGaD
Argatroban—Back pain—Etoposide—urinary bladder cancer	0.00114	0.00228	CcSEcCtD
Argatroban—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00113	0.00621	CbGpPWpGaD
Argatroban—Cardiac failure—Epirubicin—urinary bladder cancer	0.00113	0.00225	CcSEcCtD
Argatroban—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00112	0.00224	CcSEcCtD
Argatroban—Infection—Gemcitabine—urinary bladder cancer	0.00112	0.00224	CcSEcCtD
Argatroban—Confusional state—Fluorouracil—urinary bladder cancer	0.00112	0.00224	CcSEcCtD
Argatroban—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00111	0.00221	CcSEcCtD
Argatroban—Infection—Fluorouracil—urinary bladder cancer	0.0011	0.0022	CcSEcCtD
Argatroban—Renal failure acute—Doxorubicin—urinary bladder cancer	0.0011	0.0022	CcSEcCtD
Argatroban—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.0011	0.0022	CcSEcCtD
Argatroban—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.0011	0.00219	CcSEcCtD
Argatroban—Tachycardia—Fluorouracil—urinary bladder cancer	0.00108	0.00216	CcSEcCtD
Argatroban—F2—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—urinary bladder cancer	0.00108	0.00595	CbGpPWpGaD
Argatroban—Renal impairment—Doxorubicin—urinary bladder cancer	0.00107	0.00213	CcSEcCtD
Argatroban—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.00106	0.00213	CcSEcCtD
Argatroban—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00106	0.00585	CbGpPWpGaD
Argatroban—Body temperature increased—Thiotepa—urinary bladder cancer	0.00106	0.00212	CcSEcCtD
Argatroban—Abdominal pain—Thiotepa—urinary bladder cancer	0.00106	0.00212	CcSEcCtD
Argatroban—Hypotension—Gemcitabine—urinary bladder cancer	0.00106	0.00211	CcSEcCtD
Argatroban—Cardiac arrest—Epirubicin—urinary bladder cancer	0.00105	0.00209	CcSEcCtD
Argatroban—Infection—Cisplatin—urinary bladder cancer	0.00105	0.00209	CcSEcCtD
Argatroban—Cardiac failure—Doxorubicin—urinary bladder cancer	0.00104	0.00208	CcSEcCtD
Argatroban—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00104	0.00207	CcSEcCtD
Argatroban—Hypotension—Fluorouracil—urinary bladder cancer	0.00104	0.00207	CcSEcCtD
Argatroban—Cough—Etoposide—urinary bladder cancer	0.00103	0.00206	CcSEcCtD
Argatroban—Tachycardia—Cisplatin—urinary bladder cancer	0.00103	0.00205	CcSEcCtD
Argatroban—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.00102	0.00203	CcSEcCtD
Argatroban—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00101	0.00201	CcSEcCtD
Argatroban—Chest pain—Etoposide—urinary bladder cancer	0.00101	0.00201	CcSEcCtD
Argatroban—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.001	0.00551	CbGpPWpGaD
Argatroban—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000997	0.00549	CbGpPWpGaD
Argatroban—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00099	0.00198	CcSEcCtD
Argatroban—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000989	0.00197	CcSEcCtD
Argatroban—Hypotension—Cisplatin—urinary bladder cancer	0.000984	0.00196	CcSEcCtD
Argatroban—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000977	0.00195	CcSEcCtD
Argatroban—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000975	0.00195	CcSEcCtD
Argatroban—Confusional state—Etoposide—urinary bladder cancer	0.000972	0.00194	CcSEcCtD
Argatroban—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000968	0.00193	CcSEcCtD
Argatroban—Pain—Gemcitabine—urinary bladder cancer	0.000966	0.00193	CcSEcCtD
Argatroban—Constipation—Gemcitabine—urinary bladder cancer	0.000966	0.00193	CcSEcCtD
Argatroban—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000959	0.00191	CcSEcCtD
Argatroban—Infection—Etoposide—urinary bladder cancer	0.000958	0.00191	CcSEcCtD
Argatroban—Pain—Fluorouracil—urinary bladder cancer	0.00095	0.0019	CcSEcCtD
Argatroban—Tachycardia—Etoposide—urinary bladder cancer	0.000941	0.00188	CcSEcCtD
Argatroban—Dyspnoea—Cisplatin—urinary bladder cancer	0.000938	0.00187	CcSEcCtD
Argatroban—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000931	0.00186	CcSEcCtD
Argatroban—Angina pectoris—Epirubicin—urinary bladder cancer	0.000926	0.00185	CcSEcCtD
Argatroban—Diarrhoea—Thiotepa—urinary bladder cancer	0.000919	0.00183	CcSEcCtD
Argatroban—F2—Folate Metabolism—IL2—urinary bladder cancer	0.000917	0.00505	CbGpPWpGaD
Argatroban—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000915	0.00183	CcSEcCtD
Argatroban—Pneumonia—Methotrexate—urinary bladder cancer	0.000911	0.00182	CcSEcCtD
Argatroban—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000909	0.00181	CcSEcCtD
Argatroban—Hypotension—Etoposide—urinary bladder cancer	0.000901	0.0018	CcSEcCtD
Argatroban—Pain—Cisplatin—urinary bladder cancer	0.0009	0.0018	CcSEcCtD
Argatroban—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000893	0.00178	CcSEcCtD
Argatroban—Dizziness—Thiotepa—urinary bladder cancer	0.000888	0.00177	CcSEcCtD
Argatroban—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000878	0.00175	CcSEcCtD
Argatroban—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000867	0.00173	CcSEcCtD
Argatroban—Haematuria—Methotrexate—urinary bladder cancer	0.000864	0.00172	CcSEcCtD
Argatroban—Dyspnoea—Etoposide—urinary bladder cancer	0.00086	0.00172	CcSEcCtD
Argatroban—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000857	0.00171	CcSEcCtD
Argatroban—Vomiting—Thiotepa—urinary bladder cancer	0.000854	0.0017	CcSEcCtD
Argatroban—Pneumonia—Epirubicin—urinary bladder cancer	0.000853	0.0017	CcSEcCtD
Argatroban—Rash—Thiotepa—urinary bladder cancer	0.000846	0.00169	CcSEcCtD
Argatroban—Dermatitis—Thiotepa—urinary bladder cancer	0.000846	0.00169	CcSEcCtD
Argatroban—Headache—Thiotepa—urinary bladder cancer	0.000841	0.00168	CcSEcCtD
Argatroban—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—urinary bladder cancer	0.000834	0.00459	CbGpPWpGaD
Argatroban—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000833	0.00166	CcSEcCtD
Argatroban—Body temperature increased—Cisplatin—urinary bladder cancer	0.000832	0.00166	CcSEcCtD
Argatroban—Constipation—Etoposide—urinary bladder cancer	0.000825	0.00165	CcSEcCtD
Argatroban—Pain—Etoposide—urinary bladder cancer	0.000825	0.00165	CcSEcCtD
Argatroban—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000824	0.00164	CcSEcCtD
Argatroban—F2—Vitamin B12 Metabolism—TNF—urinary bladder cancer	0.000821	0.00452	CbGpPWpGaD
Argatroban—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000818	0.00163	CcSEcCtD
Argatroban—Haemoglobin—Methotrexate—urinary bladder cancer	0.000817	0.00163	CcSEcCtD
Argatroban—Haemorrhage—Methotrexate—urinary bladder cancer	0.000813	0.00162	CcSEcCtD
Argatroban—Haematuria—Epirubicin—urinary bladder cancer	0.000808	0.00161	CcSEcCtD
Argatroban—Nausea—Thiotepa—urinary bladder cancer	0.000797	0.00159	CcSEcCtD
Argatroban—Feeling abnormal—Etoposide—urinary bladder cancer	0.000795	0.00159	CcSEcCtD
Argatroban—Pneumonia—Doxorubicin—urinary bladder cancer	0.000789	0.00157	CcSEcCtD
Argatroban—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000789	0.00157	CcSEcCtD
Argatroban—F2—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000786	0.00433	CbGpPWpGaD
Argatroban—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000776	0.00155	CcSEcCtD
Argatroban—Bradycardia—Epirubicin—urinary bladder cancer	0.000775	0.00155	CcSEcCtD
Argatroban—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000773	0.00154	CcSEcCtD
Argatroban—Haemoglobin—Epirubicin—urinary bladder cancer	0.000765	0.00153	CcSEcCtD
Argatroban—Abdominal pain—Etoposide—urinary bladder cancer	0.000762	0.00152	CcSEcCtD
Argatroban—Body temperature increased—Etoposide—urinary bladder cancer	0.000762	0.00152	CcSEcCtD
Argatroban—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000762	0.00152	CcSEcCtD
Argatroban—Haemorrhage—Epirubicin—urinary bladder cancer	0.000761	0.00152	CcSEcCtD
Argatroban—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000761	0.00419	CbGpPWpGaD
Argatroban—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00076	0.00152	CcSEcCtD
Argatroban—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00075	0.00413	CbGpPWpGaD
Argatroban—Haematuria—Doxorubicin—urinary bladder cancer	0.000748	0.00149	CcSEcCtD
Argatroban—F2—Regulation of Actin Cytoskeleton—FGFR3—urinary bladder cancer	0.00074	0.00407	CbGpPWpGaD
Argatroban—Angiopathy—Methotrexate—urinary bladder cancer	0.000738	0.00147	CcSEcCtD
Argatroban—Dizziness—Fluorouracil—urinary bladder cancer	0.000734	0.00147	CcSEcCtD
Argatroban—Diarrhoea—Cisplatin—urinary bladder cancer	0.00072	0.00144	CcSEcCtD
Argatroban—Vomiting—Gemcitabine—urinary bladder cancer	0.000718	0.00143	CcSEcCtD
Argatroban—Bradycardia—Doxorubicin—urinary bladder cancer	0.000717	0.00143	CcSEcCtD
Argatroban—Rash—Gemcitabine—urinary bladder cancer	0.000712	0.00142	CcSEcCtD
Argatroban—Dermatitis—Gemcitabine—urinary bladder cancer	0.000711	0.00142	CcSEcCtD
Argatroban—Hypersensitivity—Etoposide—urinary bladder cancer	0.000711	0.00142	CcSEcCtD
Argatroban—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000708	0.00141	CcSEcCtD
Argatroban—Headache—Gemcitabine—urinary bladder cancer	0.000708	0.00141	CcSEcCtD
Argatroban—Vomiting—Fluorouracil—urinary bladder cancer	0.000706	0.00141	CcSEcCtD
Argatroban—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000704	0.00141	CcSEcCtD
Argatroban—Rash—Fluorouracil—urinary bladder cancer	0.0007	0.0014	CcSEcCtD
Argatroban—Dermatitis—Fluorouracil—urinary bladder cancer	0.000699	0.0014	CcSEcCtD
Argatroban—Headache—Fluorouracil—urinary bladder cancer	0.000696	0.00139	CcSEcCtD
Argatroban—F2—Metabolism of proteins—CDX2—urinary bladder cancer	0.000693	0.00382	CbGpPWpGaD
Argatroban—Angiopathy—Epirubicin—urinary bladder cancer	0.00069	0.00138	CcSEcCtD
Argatroban—Back pain—Methotrexate—urinary bladder cancer	0.000685	0.00137	CcSEcCtD
Argatroban—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000681	0.00375	CbGpPWpGaD
Argatroban—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000672	0.0037	CbGpPWpGaD
Argatroban—Nausea—Gemcitabine—urinary bladder cancer	0.000671	0.00134	CcSEcCtD
Argatroban—Vomiting—Cisplatin—urinary bladder cancer	0.000669	0.00134	CcSEcCtD
Argatroban—F2—Folate Metabolism—TNF—urinary bladder cancer	0.000668	0.00368	CbGpPWpGaD
Argatroban—Rash—Cisplatin—urinary bladder cancer	0.000664	0.00133	CcSEcCtD
Argatroban—Dermatitis—Cisplatin—urinary bladder cancer	0.000663	0.00132	CcSEcCtD
Argatroban—Diarrhoea—Etoposide—urinary bladder cancer	0.00066	0.00132	CcSEcCtD
Argatroban—Nausea—Fluorouracil—urinary bladder cancer	0.00066	0.00132	CcSEcCtD
Argatroban—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000646	0.00355	CbGpPWpGaD
Argatroban—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000646	0.00355	CbGpPWpGaD
Argatroban—Back pain—Epirubicin—urinary bladder cancer	0.000641	0.00128	CcSEcCtD
Argatroban—Angiopathy—Doxorubicin—urinary bladder cancer	0.000639	0.00128	CcSEcCtD
Argatroban—Dizziness—Etoposide—urinary bladder cancer	0.000638	0.00127	CcSEcCtD
Argatroban—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000637	0.00351	CbGpPWpGaD
Argatroban—Nausea—Cisplatin—urinary bladder cancer	0.000625	0.00125	CcSEcCtD
Argatroban—Cough—Methotrexate—urinary bladder cancer	0.000618	0.00123	CcSEcCtD
Argatroban—Vomiting—Etoposide—urinary bladder cancer	0.000613	0.00122	CcSEcCtD
Argatroban—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000608	0.00335	CbGpPWpGaD
Argatroban—Rash—Etoposide—urinary bladder cancer	0.000608	0.00121	CcSEcCtD
Argatroban—Dermatitis—Etoposide—urinary bladder cancer	0.000607	0.00121	CcSEcCtD
Argatroban—Headache—Etoposide—urinary bladder cancer	0.000604	0.00121	CcSEcCtD
Argatroban—Chest pain—Methotrexate—urinary bladder cancer	0.000603	0.0012	CcSEcCtD
Argatroban—Back pain—Doxorubicin—urinary bladder cancer	0.000593	0.00118	CcSEcCtD
Argatroban—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00059	0.00325	CbGpPWpGaD
Argatroban—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.00059	0.00325	CbGpPWpGaD
Argatroban—F2—Folate Metabolism—TP53—urinary bladder cancer	0.000589	0.00324	CbGpPWpGaD
Argatroban—Confusional state—Methotrexate—urinary bladder cancer	0.000582	0.00116	CcSEcCtD
Argatroban—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000582	0.00321	CbGpPWpGaD
Argatroban—F2—Cell surface interactions at the vascular wall—SRC—urinary bladder cancer	0.000579	0.00319	CbGpPWpGaD
Argatroban—Cough—Epirubicin—urinary bladder cancer	0.000578	0.00115	CcSEcCtD
Argatroban—Infection—Methotrexate—urinary bladder cancer	0.000574	0.00115	CcSEcCtD
Argatroban—Nausea—Etoposide—urinary bladder cancer	0.000573	0.00114	CcSEcCtD
Argatroban—F2—Regulation of Actin Cytoskeleton—RHOA—urinary bladder cancer	0.00057	0.00314	CbGpPWpGaD
Argatroban—Chest pain—Epirubicin—urinary bladder cancer	0.000564	0.00113	CcSEcCtD
Argatroban—Confusional state—Epirubicin—urinary bladder cancer	0.000545	0.00109	CcSEcCtD
Argatroban—Hypotension—Methotrexate—urinary bladder cancer	0.00054	0.00108	CcSEcCtD
Argatroban—Infection—Epirubicin—urinary bladder cancer	0.000537	0.00107	CcSEcCtD
Argatroban—Cough—Doxorubicin—urinary bladder cancer	0.000535	0.00107	CcSEcCtD
Argatroban—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000532	0.00293	CbGpPWpGaD
Argatroban—F2—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000531	0.00292	CbGpPWpGaD
Argatroban—Tachycardia—Epirubicin—urinary bladder cancer	0.000528	0.00105	CcSEcCtD
Argatroban—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000524	0.00289	CbGpPWpGaD
Argatroban—Chest pain—Doxorubicin—urinary bladder cancer	0.000522	0.00104	CcSEcCtD
Argatroban—Dyspnoea—Methotrexate—urinary bladder cancer	0.000515	0.00103	CcSEcCtD
Argatroban—Dyspepsia—Methotrexate—urinary bladder cancer	0.000508	0.00102	CcSEcCtD
Argatroban—Hypotension—Epirubicin—urinary bladder cancer	0.000505	0.00101	CcSEcCtD
Argatroban—Confusional state—Doxorubicin—urinary bladder cancer	0.000504	0.00101	CcSEcCtD
Argatroban—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000499	0.000996	CcSEcCtD
Argatroban—Infection—Doxorubicin—urinary bladder cancer	0.000497	0.000992	CcSEcCtD
Argatroban—Pain—Methotrexate—urinary bladder cancer	0.000494	0.000986	CcSEcCtD
Argatroban—Tachycardia—Doxorubicin—urinary bladder cancer	0.000488	0.000975	CcSEcCtD
Argatroban—Dyspnoea—Epirubicin—urinary bladder cancer	0.000482	0.000962	CcSEcCtD
Argatroban—F2—Cell surface interactions at the vascular wall—KRAS—urinary bladder cancer	0.000479	0.00264	CbGpPWpGaD
Argatroban—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000476	0.00095	CcSEcCtD
Argatroban—Dyspepsia—Epirubicin—urinary bladder cancer	0.000476	0.00095	CcSEcCtD
Argatroban—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000472	0.000943	CcSEcCtD
Argatroban—Hypotension—Doxorubicin—urinary bladder cancer	0.000467	0.000933	CcSEcCtD
Argatroban—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000467	0.000932	CcSEcCtD
Argatroban—Constipation—Epirubicin—urinary bladder cancer	0.000462	0.000923	CcSEcCtD
Argatroban—Pain—Epirubicin—urinary bladder cancer	0.000462	0.000923	CcSEcCtD
Argatroban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000458	0.00252	CbGpPWpGaD
Argatroban—Abdominal pain—Methotrexate—urinary bladder cancer	0.000457	0.000912	CcSEcCtD
Argatroban—Body temperature increased—Methotrexate—urinary bladder cancer	0.000457	0.000912	CcSEcCtD
Argatroban—F2—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.000454	0.0025	CbGpPWpGaD
Argatroban—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000446	0.00089	CcSEcCtD
Argatroban—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000445	0.000889	CcSEcCtD
Argatroban—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000442	0.000883	CcSEcCtD
Argatroban—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00044	0.000879	CcSEcCtD
Argatroban—F2—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000435	0.0024	CbGpPWpGaD
Argatroban—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000432	0.000862	CcSEcCtD
Argatroban—Pain—Doxorubicin—urinary bladder cancer	0.000428	0.000854	CcSEcCtD
Argatroban—Constipation—Doxorubicin—urinary bladder cancer	0.000428	0.000854	CcSEcCtD
Argatroban—Abdominal pain—Epirubicin—urinary bladder cancer	0.000427	0.000853	CcSEcCtD
Argatroban—Body temperature increased—Epirubicin—urinary bladder cancer	0.000427	0.000853	CcSEcCtD
Argatroban—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000426	0.00085	CcSEcCtD
Argatroban—F2—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.000416	0.00229	CbGpPWpGaD
Argatroban—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000412	0.000823	CcSEcCtD
Argatroban—F2—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000412	0.00227	CbGpPWpGaD
Argatroban—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000409	0.000817	CcSEcCtD
Argatroban—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000409	0.00225	CbGpPWpGaD
Argatroban—F2—Cell surface interactions at the vascular wall—HRAS—urinary bladder cancer	0.000407	0.00224	CbGpPWpGaD
Argatroban—F2—Hemostasis—IFNA2—urinary bladder cancer	0.000405	0.00223	CbGpPWpGaD
Argatroban—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000403	0.00222	CbGpPWpGaD
Argatroban—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000398	0.000795	CcSEcCtD
Argatroban—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000395	0.000789	CcSEcCtD
Argatroban—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000395	0.000789	CcSEcCtD
Argatroban—Diarrhoea—Methotrexate—urinary bladder cancer	0.000395	0.000789	CcSEcCtD
Argatroban—Dizziness—Methotrexate—urinary bladder cancer	0.000382	0.000763	CcSEcCtD
Argatroban—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000376	0.00207	CbGpPWpGaD
Argatroban—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000371	0.00204	CbGpPWpGaD
Argatroban—Diarrhoea—Epirubicin—urinary bladder cancer	0.00037	0.000738	CcSEcCtD
Argatroban—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000369	0.000736	CcSEcCtD
Argatroban—Vomiting—Methotrexate—urinary bladder cancer	0.000367	0.000733	CcSEcCtD
Argatroban—F2—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	0.000366	0.00201	CbGpPWpGaD
Argatroban—Rash—Methotrexate—urinary bladder cancer	0.000364	0.000727	CcSEcCtD
Argatroban—Dermatitis—Methotrexate—urinary bladder cancer	0.000364	0.000726	CcSEcCtD
Argatroban—Headache—Methotrexate—urinary bladder cancer	0.000362	0.000722	CcSEcCtD
Argatroban—Dizziness—Epirubicin—urinary bladder cancer	0.000357	0.000714	CcSEcCtD
Argatroban—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000354	0.00195	CbGpPWpGaD
Argatroban—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000349	0.00192	CbGpPWpGaD
Argatroban—F2—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	0.000349	0.00192	CbGpPWpGaD
Argatroban—F2—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	0.000345	0.0019	CbGpPWpGaD
Argatroban—Vomiting—Epirubicin—urinary bladder cancer	0.000344	0.000686	CcSEcCtD
Argatroban—Nausea—Methotrexate—urinary bladder cancer	0.000343	0.000685	CcSEcCtD
Argatroban—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000342	0.000683	CcSEcCtD
Argatroban—Rash—Epirubicin—urinary bladder cancer	0.000341	0.00068	CcSEcCtD
Argatroban—Dermatitis—Epirubicin—urinary bladder cancer	0.000341	0.00068	CcSEcCtD
Argatroban—Headache—Epirubicin—urinary bladder cancer	0.000339	0.000676	CcSEcCtD
Argatroban—Dizziness—Doxorubicin—urinary bladder cancer	0.000331	0.00066	CcSEcCtD
Argatroban—Nausea—Epirubicin—urinary bladder cancer	0.000321	0.000641	CcSEcCtD
Argatroban—Vomiting—Doxorubicin—urinary bladder cancer	0.000318	0.000635	CcSEcCtD
Argatroban—Rash—Doxorubicin—urinary bladder cancer	0.000315	0.00063	CcSEcCtD
Argatroban—Dermatitis—Doxorubicin—urinary bladder cancer	0.000315	0.000629	CcSEcCtD
Argatroban—Headache—Doxorubicin—urinary bladder cancer	0.000313	0.000626	CcSEcCtD
Argatroban—F2—Signaling Pathways—HDAC4—urinary bladder cancer	0.000312	0.00172	CbGpPWpGaD
Argatroban—F2—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000304	0.00168	CbGpPWpGaD
Argatroban—Nausea—Doxorubicin—urinary bladder cancer	0.000297	0.000593	CcSEcCtD
Argatroban—F2—Hemostasis—PLAU—urinary bladder cancer	0.000287	0.00158	CbGpPWpGaD
Argatroban—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000283	0.00156	CbGpPWpGaD
Argatroban—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000276	0.00152	CbGpPWpGaD
Argatroban—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000274	0.00151	CbGpPWpGaD
Argatroban—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000273	0.0015	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—GLI1—urinary bladder cancer	0.000261	0.00144	CbGpPWpGaD
Argatroban—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000258	0.00142	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000251	0.00138	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000237	0.00131	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000237	0.00131	CbGpPWpGaD
Argatroban—F2—Hemostasis—CREBBP—urinary bladder cancer	0.000237	0.0013	CbGpPWpGaD
Argatroban—F2—Hemostasis—IGF1—urinary bladder cancer	0.000234	0.00129	CbGpPWpGaD
Argatroban—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000219	0.00121	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.000217	0.0012	CbGpPWpGaD
Argatroban—F2—Hemostasis—RHOA—urinary bladder cancer	0.000214	0.00118	CbGpPWpGaD
Argatroban—F2—GPCR ligand binding—CXCL8—urinary bladder cancer	0.00021	0.00116	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	0.000196	0.00108	CbGpPWpGaD
Argatroban—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.00019	0.00105	CbGpPWpGaD
Argatroban—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000188	0.00103	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	0.000185	0.00102	CbGpPWpGaD
Argatroban—F2—Metabolism of proteins—IGF1—urinary bladder cancer	0.000184	0.00101	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	0.00018	0.000991	CbGpPWpGaD
Argatroban—F2—Hemostasis—IL2—urinary bladder cancer	0.00018	0.00099	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—RBX1—urinary bladder cancer	0.000179	0.000985	CbGpPWpGaD
Argatroban—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000175	0.000962	CbGpPWpGaD
Argatroban—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000172	0.000949	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—TSC1—urinary bladder cancer	0.000168	0.000927	CbGpPWpGaD
Argatroban—F2—Hemostasis—EP300—urinary bladder cancer	0.000161	0.000888	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—JAG1—urinary bladder cancer	0.00016	0.000882	CbGpPWpGaD
Argatroban—F2—Hemostasis—SRC—urinary bladder cancer	0.000157	0.000864	CbGpPWpGaD
Argatroban—F2—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000148	0.000815	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—TYMP—urinary bladder cancer	0.000144	0.000792	CbGpPWpGaD
Argatroban—F2—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000135	0.000746	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—NAT2—urinary bladder cancer	0.00013	0.000716	CbGpPWpGaD
Argatroban—F2—Hemostasis—KRAS—urinary bladder cancer	0.00013	0.000715	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—S100B—urinary bladder cancer	0.00013	0.000714	CbGpPWpGaD
Argatroban—F2—Signaling by GPCR—RHOA—urinary bladder cancer	0.000123	0.000677	CbGpPWpGaD
Argatroban—F2—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000119	0.000655	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—NCOR1—urinary bladder cancer	0.000117	0.000642	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000116	0.000641	CbGpPWpGaD
Argatroban—F2—Hemostasis—TP53—urinary bladder cancer	0.000115	0.000636	CbGpPWpGaD
Argatroban—F2—GPCR downstream signaling—IL2—urinary bladder cancer	0.000114	0.000626	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—RRM2—urinary bladder cancer	0.000112	0.000618	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	0.00011	0.000608	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—NAT1—urinary bladder cancer	0.00011	0.000608	CbGpPWpGaD
Argatroban—F2—Hemostasis—HRAS—urinary bladder cancer	0.00011	0.000608	CbGpPWpGaD
Argatroban—F2—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000108	0.000594	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	0.000104	0.000573	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—ENO2—urinary bladder cancer	0.000104	0.000573	CbGpPWpGaD
Argatroban—F2—Signaling by GPCR—IL2—urinary bladder cancer	0.000103	0.000568	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—TERT—urinary bladder cancer	0.000103	0.000566	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	0.000101	0.000556	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	0.000101	0.000556	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—FGFR3—urinary bladder cancer	9.43e-05	0.000519	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—ESR1—urinary bladder cancer	9.16e-05	0.000504	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	9.09e-05	0.000501	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.59e-05	0.000473	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—NQO1—urinary bladder cancer	8.38e-05	0.000462	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.37e-05	0.000461	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—CREBBP—urinary bladder cancer	8.03e-05	0.000442	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—IGF1—urinary bladder cancer	7.93e-05	0.000437	CbGpPWpGaD
Argatroban—F2—Signaling by GPCR—EGFR—urinary bladder cancer	7.89e-05	0.000434	CbGpPWpGaD
Argatroban—F2—Signaling by GPCR—KRAS—urinary bladder cancer	7.45e-05	0.00041	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—RHOA—urinary bladder cancer	7.26e-05	0.0004	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	6.99e-05	0.000385	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—ERBB2—urinary bladder cancer	6.72e-05	0.00037	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.69e-05	0.000368	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—TYMS—urinary bladder cancer	6.5e-05	0.000358	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	6.43e-05	0.000354	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	6.43e-05	0.000354	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—CXCL8—urinary bladder cancer	6.38e-05	0.000351	CbGpPWpGaD
Argatroban—F2—Signaling by GPCR—HRAS—urinary bladder cancer	6.34e-05	0.000349	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—GPX1—urinary bladder cancer	6.15e-05	0.000339	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—IL2—urinary bladder cancer	6.09e-05	0.000336	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.05e-05	0.000333	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	6.04e-05	0.000333	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—CCND1—urinary bladder cancer	5.94e-05	0.000327	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—MMP9—urinary bladder cancer	5.77e-05	0.000318	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.75e-05	0.000316	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—PTEN—urinary bladder cancer	5.73e-05	0.000316	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	5.68e-05	0.000313	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—EP300—urinary bladder cancer	5.47e-05	0.000301	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—SRC—urinary bladder cancer	5.32e-05	0.000293	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.22e-05	0.000288	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.84e-05	0.000266	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.84e-05	0.000266	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—MYC—urinary bladder cancer	4.77e-05	0.000262	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.69e-05	0.000258	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—EGFR—urinary bladder cancer	4.66e-05	0.000257	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—PPARG—urinary bladder cancer	4.61e-05	0.000254	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	4.42e-05	0.000244	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—KRAS—urinary bladder cancer	4.4e-05	0.000242	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—TP53—urinary bladder cancer	3.91e-05	0.000215	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.9e-05	0.000215	CbGpPWpGaD
Argatroban—F2—Signaling Pathways—HRAS—urinary bladder cancer	3.74e-05	0.000206	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	3.62e-05	0.000199	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.25e-05	0.000179	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—PTEN—urinary bladder cancer	3.16e-05	0.000174	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.02e-05	0.000166	CbGpPWpGaD
Argatroban—CYP3A5—Metabolism—EP300—urinary bladder cancer	3.01e-05	0.000166	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.99e-05	0.000165	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.99e-05	0.000165	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.86e-05	0.000158	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.81e-05	0.000155	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.64e-05	0.000145	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.14e-05	0.000118	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.06e-05	0.000113	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.68e-05	9.27e-05	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.47e-05	8.09e-05	CbGpPWpGaD
Argatroban—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.4e-05	7.71e-05	CbGpPWpGaD
